相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
Angela Cho et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres Poveda et al.
LANCET ONCOLOGY (2021)
Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis
Carrie M. Nielson et al.
ONCOLOGIST (2021)
Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study
Hong Zheng et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel
Domenica Lorusso et al.
SUPPORTIVE CARE IN CANCER (2020)
The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients
Wanwan Qi et al.
SCIENTIFIC REPORTS (2020)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and dose modification for patients receiving niraparib
J. S. Berek et al.
ANNALS OF ONCOLOGY (2018)
Olaparib in German routine clinical practice: Updated interim results of the non-interventional study c-patrol
J. Sehouli et al.
GYNECOLOGIC ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
Irene Eriksson et al.
TARGETED ONCOLOGY (2018)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
2755 First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)
T. De La Motte Rouge et al.
EUROPEAN JOURNAL OF CANCER (2016)
Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer
Michael Friedlander et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Systematic Review of Adherence to Oral Antineoplastic Therapies
Joseph A. Greer et al.
ONCOLOGIST (2016)
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer
Kathleen N. Moore et al.
ONCOLOGIST (2016)
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J. Mateo et al.
TARGETED ONCOLOGY (2016)
A review of relative dose intensity and survival in patients with metastatic solid tumors
Laura J. Havrilesky et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
Lucien Noens et al.
HAEMATOLOGICA (2014)
Challenges of Guarantee-Time Bias
Anita Giobbie-Hurder et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Caitlin C. Murphy et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables
James R. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
